MTOR and pancreatic insulinoma: Everolimus, a mammalian target of rapamycin inhibitor, has shown efficacy in treating pancreatic neuroendocrine tumors, including insulinomas, by inhibiting the mammalian target of rapamycin (mTOR) pathway.